Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2016 August;107(4) > Minerva Medica 2016 August;107(4):251-8

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2016 August;107(4):251-8

    REVIEWS

Long non-coding RNA H19 can predict a poor prognosis and lymph node metastasis: a meta-analysis in human cancer

Tao CHEN 1, Peng YANG 1, Zhen Y. HE 2

1 The Second Clinical Medical College of Nanjing Medical University, Nanjing, China; 2 Department of General Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

INTRODUCTION: A long non-coding RNA (lncRNA) H19 has been reported to be aberrantly regulated in a wide range of cancers. This meta-analysis was performed to explore the potential value of H19 as a biomarker for cancer prognosis.
EVIDENCE ACQUISITION: We searched the electronic databases PubMed and Web of Science (up to April 30, 2016) in attention to collect all relevant researches to identify the association of lncRNA H19 with overall survival (OS), disease free survival (DFS) and lymph node metastasis (LNM).
EVIDENCE SYNTHESIS: Our findings revealed that high levels of H19 expression could predict poor OS (pooled HR: 1.19, 95% CI: 1.08-1.32, P=0.001) and LNM (pooled OR: 1.810, 95% CI: 1.27-2.59, P=0.001) in multiple cancers.
CONCLUSIONS: This meta-analysis showed that overexpression of H19 might potentially serve as a reliable biomarker for poor prognosis in different types of cancers.

language: English


FULL TEXT  REPRINTS

top of page